13 documents found, page 1 of 2
Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathwa...
Moranguinho, Inês; Taveira, Nuno; Bártolo, InêsCurrently, it is estimated that 1–2 million people worldwide are infected with HIV-2, accounting for 3–5% of the global burden of HIV. The course of HIV-2 infection is longer compared to HIV-1 infection, but without effective antiretroviral therapy (ART), a substantial proportion of infected patients will progress to AIDS and die. Antiretroviral drugs in clinical use were designed for HIV-1 and, unfortunately, ...
Antiretroviral treatment of HIV-2 infection : available drugs, resistance pathw...
Moranguinho, Inês; Taveira, Nuno; Bártolo, InêsCurrently, it is estimated that 1–2 million people worldwide are infected with HIV-2, accounting for 3–5% of the global burden of HIV. The course of HIV-2 infection is longer compared to HIV-1 infection, but without effective antiretroviral therapy (ART), a substantial proportion of infected patients will progress to AIDS and die. Antiretroviral drugs in clinical use were designed for HIV-1 and, unfortunately, ...
Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isola...
Martin, Francisco; Marcelino, José Maria; Palladino, Claudia; Bártolo, Inês; Tracana, Susana; Moranguinho, Inês; Gonçalves, Paloma; Mateus, RitaA minority of HIV-1-infected patients produce broadly neutralizing antibodies (bNAbs). Identification of viral and host correlates of bNAb production may help develop vaccines. We aimed to characterize the neutralizing response and viral and host-associated factors in Angola, which has one of the oldest, most dynamic, and most diverse HIV-1 epidemics in the world. Three hundred twenty-two HIV-1- infected adults...
Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isola...
Martin, Francisco; Marcelino, José Maria; Palladino, Claudia; Bártolo, Inês; Tracana, Susana; Moranguinho, Inês; Gonçalves, Paloma; Mateus, RitaA minority of HIV-1-infected patients produce broadly neutralizing antibodies (bNAbs). Identification of viral and host correlates of bNAb production may help develop vaccines. We aimed to characterize the neutralizing response and viral and host-associated factors in Angola, which has one of the oldest, most dynamic, and most diverse HIV-1 epidemics in the world. Three hundred twenty-two HIV-1-infected adults ...
Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isola...
Martin, Francisco; Marcelino, José Maria; Palladino, Claudia; Bártolo, Inês; Tracana, Susana; Moranguinho, Inês; Gonçalves, Paloma; Mateus, RitaA minority of HIV-1-infected patients produce broadly neutralizing antibodies (bNAbs). Identification of viral and host correlates of bNAb production may help develop vaccines. We aimed to characterize the neutralizing response and viral and host-associated factors in Angola, which has one of the oldest, most dynamic, and most diverse HIV-1 epidemics in the world. Three hundred twenty-two HIV-1-infected adults ...
High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-ß-Lact...
Bártolo, Inês; Moranguinho, Inês; Gonçalves, Paloma; Ana Rita Diniz; Borrego, Pedro; Martin, Francisco; Figueiredo, Inês; Gomes, PerpetuaIntegrase inhibitors (INIs) are an important class of drugs for treating HIV-2 infection, given the limited number of drugs active against this virus. While the clinical efficacy of raltegravir and dolutegravir is well established, the clinical efficacy of bictegravir for treating HIV-2 infected patients has not been determined. Little information is available regarding the activity of bictegravir against HIV-2...
High instantaneous inhibitory potential of Bictegravir and the new Spiro-β-Lact...
Bártolo, Inês; Moranguinho, Inês; Gonçalves, Paloma; Diniz, Ana Rita; Borrego, Pedro; Martin, Francisco; Figueiredo, Inês; Gomes, PerpétuaIntegrase inhibitors (INIs) are an important class of drugs for treating HIV-2 infection, given the limited number of drugs active against this virus. While the clinical efficacy of raltegravir and dolutegravir is well established, the clinical efficacy of bictegravir for treating HIV-2 infected patients has not been determined. Little information is available regarding the activity of bictegravir against HIV-2...
Long-term and low-level envelope C2V3 stimulation by highly diverse virus isola...
Martin, Francisco; Marcelino, José Maria; Palladino, Claudia; Bártolo, Inês; Tracana, Susana; Moranguinho, Inês; Gonçalves, Paloma; Mateus, RitaA minority of HIV-1-infected patients produce broadly neutralizing antibodies (bNAbs). Identification of viral and host correlates of bNAb production may help develop vaccines. We aimed to characterize the neutralizing response and viral and host-associated factors in Angola, which has one of the oldest, most dynamic, and most diverse HIV-1 epidemics in the world. Three hundred twenty-two HIV-1-infected adults ...
Genotypic resistance profiles of HIV-2 infected patients from Cape Verde failin...
Moranguinho, Inês; Borrego, Pedro; Gonçalves, Fátima; Gomes, Perpétua; Rocha, José; Barreto, Jorge; Taveira, NunoThe pol gene from HIV-2 infected patients from Cape Verde experiencing virologic failure was sequenced and drug resistance mutations were determined. Most patients were taking a first line regimen of AZT, 3TC and LPV/r. Resistance mutations were found in most patients (11/17, 64.7%) especially I82F (4/7, 57.1%) and M184 V (10/17, 58.8%). Resistance to all reverse transcriptase and protease inhibitors was found ...
Epidemic history of hepatitis C virus genotypes and subtypes in Portugal
Palladino, Claudia; Ezeonwumelu, Ifeanyi Jude; Marcelino, Rute; Briz, Verónica; Moranguinho, Inês; Serejo, Fátima; Velosa, José FernandoAny successful strategy to prevent and control HCV infection requires an understanding of the epidemic behaviour among the different genotypes. Here, we performed the first characterization of the epidemic history and transmission dynamics of HCV subtypes in Portugal. Direct sequencing of NS5B was performed on 230 direct-acting antiviral drugs (DAA)-treatment naïve patients in Lisbon. Phylogenetic analysis was ...